Page 77 - GTM-1-1

Global Translational Medicine ctDNA in management of patients with NSCLC

Apart from prediction of therapeutic response, ctDNA Writing – original draft: Yi-Chen Jin, Man-Qi Wu,
can monitor the formation of drug resistance in real- Ke-Zhong Chen
time. Horn et al. studied longitudinal ctDNA dynamic Writing – review & editing: Ke-Zhong Chen, Jun Wang.
[74]
changes during ALK TKI procedure in 76 patients
with ALK+NSCLC who were enrolled in the Phase I/II References
multicohort eXalt2 trial. Various baseline subset mutations 1. Sung H, Ferlay J, Siegel RL, et al., 2021, Global cancer
at ALK were observed and dynamic changes of mutation statistics 2020: GLOBOCAN estimates of incidence and
proportion or types happened as the therapy went on. mortality worldwide for 36 cancers in 185 countries. CA
In a classical case, the patient who had prior medication Cancer J Clin, 71(3): 209–249.
history of crizotinib and ceritinib had ALK L1152V https://doi.org/10.3322/caac.21660
and G1269A baseline mutations, but these mutations
disappeared when he experienced partial response during 2. Thai AA, Solomon BJ, Sequist LV, et al., 2021, Lung cancer.
ensartinib treatment. At last, new ALK mutation E1210K Lancet, 398(10299): 535–554.
was detected at the time of radiographic progression. This https://doi.org/10.1016/S0140-6736(21)00312-3
research suggests that ctDNA can monitor dynamic clonal 3. Goldstraw P, Chansky K, Crowley J, et al., 2016, The IASLC
evolution and guide selective pressures by therapy . lung cancer staging project: Proposals for revision of the
[8]
As for the future direction of this field, the timepoint to TNM stage groupings in the forthcoming (Eighth) edition
check ctDNA and modulate therapy schedule is definitely of the TNM classification for lung cancer. J Thorac Oncol,
major research topics in MRD detection. Recent studies lack a 11(1): 39–51.
unified standard and literature focusing on NSCLC in dynamic https://doi.org/10.1016/j.jtho.2015.09.009
evolution during adjuvant therapy are scarce . Balancing 4. Pantel K, Alix-Panabières C, 2017, Tumour
[16]
the benefit and toxicity to decide the most appropriate time microenvironment: Informing on minimal residual disease
to withdraw or escalate the therapy will undoubtedly achieve in solid tumours. Nat Rev Clin Oncol, 14(6): 325–326.
maximum benefits for patients of all stages .
[75]
https://doi.org/10.1038/nrclinonc.2017.53
5. Summary 5. Diaz LA Jr., Bardelli A, 2014, Liquid biopsies: Genotyping
ctDNA is a potential biomarker, which plays an instrumental circulating tumor DNA. J Clin Oncol, 32(6): 579–586.
role in the whole treatment process of NSCLC with high https://doi.org/10.1200/JCO.2012.45.2011
accuracy. It demonstrates wide utility in early detection 6. Avanzini S, Kurtz DM, Chabon JJ, et al., 2020, A mathematical
to screen underlying cancer, in MRD detection to predict model of ctDNA shedding predicts tumor detection size. Sci
long-term prognosis, and in treatment arrangement to Adv, 6(50): eabc4308.
guide more precise and effective therapeutic schedule.
https://doi.org/10.1126/sciadv.abc4308
Acknowledgments 7. Jaiswal S, Fontanillas P, Flannick J, et al., 2014, Age-related
clonal hematopoiesis associated with adverse outcomes.
We thank Kai Zhang and Su-Jie Zhang for their guidance N Engl J Med, 371(26): 2488–2498.
and inspiration on this review’s structure and arguments.
8. Siravegna G, Marsoni S, Siena S, et al., 2017, Integrating
Funding liquid biopsies into the management of cancer. Nat Rev Clin
Oncol, 14(9): 531–548.
This study was supported by Research Unit of Intelligence
Diagnosis and Treatment in Early NSCLC, Chinese https://doi.org/10.1038/nrclinonc.2017.14
Academy of Medical Sciences (2021RU002), National 9. Zhao H, Chen KZ, Hui BG, et al., 2018, Role of circulating
Natural Science Foundation of China (No. 82072566) tumor DNA in the management of early-stage lung cancer.
and Peking University People’s Hospital Research and Thorac Cancer, 9(5): 509–515.
Development Funds (RS2019-01). https://doi.org/10.1111 / 1759-7714.12622
Conflict of interest 10. Mouliere F, Rosenfeld N, 2015, Circulating tumor-derived
DNA is shorter than somatic DNA in plasma. Proc Natl
No potential conflicts of interest were disclosed. Acad Sci U S A, 112(11): 3178–3179.
Author contribution 11. Chen K, Zhao H, Shi Y, et al., 2019, Perioperative dynamic
changes in circulating tumor DNA in patients with lung
Conceptualization: Yi-Chen Jin, Man-Qi Wu, Ke-Zhong cancer (DYNAMIC). Clin Cancer Res, 25(23): 7058–7067.
Chen https://doi.org/10.1158 / 1078-0432.CCR-19-1213

Volume 1 Issue 1 (2022) 10 https://doi.org/10.36922/gtm.v1i1.96